-+ 0.00%
-+ 0.00%
-+ 0.00%
Windward Bio prices $175 million Nasdaq IPO
Share
Listen to the news
Windward Bio prices $175 million Nasdaq IPO
  • Windward Bio priced a $175 million Nasdaq IPO, excluding the greenshoe option.
  • A concurrent $50 million private placement with Sanofi brings expected gross proceeds from both transactions to $225 million.
  • Novo Holdings invested in Windward in January 2025.
  • In September 2026, Windward reported positive interim asthma results for WIN378 and initiated Phase 3.
  • Windward develops ultra-long-acting antibodies for respiratory and dermatological diseases; lead candidate WIN378 is designed for twice-yearly dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending